Analysis of temporary disability in patients with post-COVID-19 infection
https://doi.org/10.51523/2708-6011.2026-23-1-13
Abstract
Objective. To assess the structure and duration of temporary disability (TD) in patients with post-COVID-19 infection.
Materials and methods. A single-center cohort study was conducted involving 137 patients observed at Gomel Central City Clinical Polyclinic (GCCCP), Branch No. 12 from 2021 to 2025. Women accounted for 67.2% (92 people) of the study cohort of patients, and men – 32.8% (45 people). 81% (111 people) of patients were of working age.
Results. Temporary disability certificates were not issued to only 14.6% of patients with post-COVID-19 infection conditions during the entire observation period. The most common types of temporary disability were single or double cases. The average duration of the case (ADC) of temporary disability in non-working patients was longer, amounting to 24.8 (p=0,045) in 2022, 48.5 (p=0,0006) in 2023, and 24.5 (p=0,016) in 2024, compared to 15.0, 21.0, and 18.5 (p=0,016) in 2024 among working-age patients. Among the causes of temporary disability in patients of working age, the most common were acute respiratory viral infections (ARVI), injuries and back pain, while in patients of non-working age, the most common were ARVI, arterial hypertension (AH) and joint diseases.
Conclusion. A known history of acute COVID-19 infection did not reveal a significant impact on the incidence, frequency, and structure of temporary disability.
Supporting agencies: The study was conducted within the State Program of Scientific Research 4 ‟Translational Medicine”, Subprogram 4.2 ‟Fundamental Aspects of Medical Science”: ‟3.38 Develop an algorithm for predicting post-COVID-19 associated pathology based on the study of clinical, laboratory and functional indicators in 2022-2024”.
References
1. Smirnov A.V. Demographic and Economic Consequences of the COVID-19 Pandemic in the Russian Federation. DEMIS. Demographic Research. 2025;5(2):22-39. [date of access: 17.09.2025]. Available from: https://cyberleninka.ru/article/n/demograficheskie-iekonomicheskie-posledstviya-pandemii-covid-19-v-rossiyskoyfederatsii (In Russ.).
2. Savina TN, Minaeva ОА, Ivanov EP, Rodin MA, Lebedeva АА. The impact of the COVID-19 pandemic on economic growth. Herald of the Mosсow University of Finances and Law MFUA. 2024;(1):24-39. (In Russ.).
3. Barfar E, Raei B, Daneshi S, Bagher Barahouei F, Hushmandi K. The burden of COVID-19 based on disability-adjusted life years: a systematic review of available evidence. Front Public Health. 2025;13:1401726. DOI: https://doi.org/10.3389/fpubh.2025.1401726
4. Chung Y.S., Lam C.Y., Tan P.H. et al. Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies. Int J Mol Sci. 2024;25(15):8155. DOI: https://doi.org/10.3390/ijms25158155
5. Peter RS, Nieters A, Göpel S, Merle U, Steinacker JM, Deibert P, et al. Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study. PLoS Med. 2025;22(1):e1004511. DOI: https://doi.org/10.1371/journal.pmed.1004511
6. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:3026. DOI: https://doi.org/10.1136/bmj.m3026
7. Shah W, Hillman T, Playford ED, et al. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:136. DOI: https://doi.org/10.1136/bmj.n136
8. Vlaming-van Eijk LE, Tang G, Bourgonje AR, et al. PostCOVID-19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies. J Pathol. 2025;266(4-5):369-389. DOI: https://doi.org/10.1002/path.6443
9. Nuber-Champier A, Breville G, Voruz P, Jacot de Alcântara I, Lalive PH, Allali G, et al. Inflammatory predictors of Post-COVID fatigue. Brain Behav Immun Health. 2025;49:101109. DOI: https://doi.org/10.1016/j.bbih.2025.101109
10. Barichello T, Kluwe-Schiavon B, Borba LA, Pedro LC, Niero FS, Dos Santos LN, et al. Alterations in Gut Microbiome Composition and Increased Inflammatory Markers in PostCOVID-19 Individuals. Mol Neurobiol. 2025;62(6):8038-8047. DOI: https://doi.org/10.1007/s12035-025-04769-w
11. Mink S, Wilhelm F, Cadamuro J, Reimann P, Fraunberger P. Anti-SARS-CoV-2 Antibodies in Long-COVID-Markers of Protection or Elevated Risk? A Systematic Review. Rev Med Virol. 2025;35(2):e70027. DOI: https://doi.org/10.1002/rmv.70027
12. Wang R, Lin M, Yu S, Xue X, Hu X, Wang Z. Predictors of post-COVID-19 syndrome: a meta-analysis. J Infect Dev Ctries. 2025;19(4):490-497. DOI: https://doi.org/10.3855/jidc.18574
13. Meyer M, Jonveaux T, Banasiak C, Bié M, Cartz Piver L, Chatelain A. Long-term neuropsychological consequences of severe COVID-19 infection: the NEUROCOG-COVID study. J Neurol. 2025;272(5):363. DOI: https://doi.org/10.1007/s00415-025-13097-x
14. Gasnier M, Pinson P, Beeker N, Truong-Allié C, Becquemont L, Falissard B, Corruble E, Colle R. Acute COVID-19 severity markers predict post-COVID new-onset psychiatric disorders: A 2-year cohort study of 34,489 patients. Mol Psychiatry. 2025 Apr;30(4):1329-1337. DOI: https://doi.org/10.1038/s41380-024-02739-7
15. Stoma IO, Baranov OYu, Belyakov NA, Halinouskaya NV, Voropaev EV, et al. Changes in morphometric and neurochemical parameters of brain structure in patients with post-COVID syndrome. Proceedings of the National Academy of Sciences of Belarus. Medical series. 2025;22(2):102-118. (in Russ.). DOI: https://doi.org/10.29235/1814-6023-2025-22-2-102-118
Review
For citations:
Nikiforova O.L. Analysis of temporary disability in patients with post-COVID-19 infection. Health and Ecology Issues. 2026;23(1):111-118. (In Russ.) https://doi.org/10.51523/2708-6011.2026-23-1-13
Views:
109
JATS XML
Email this article 